Autoimmune diseases comprise more than 80 chronic conditions that collectively affect approximately 5 to 8 % of the US population and are a leading cause of death in young and middle-aged women.
OncOlOgy & HematOlOgy Review maintain immunologic self-tolerance. Organ damage and the ensuing clinical manifestations may result from the action of autoantibodies, self-reactive effector T cell (Teff) responses, secreted cytokines, or other elements that participate in the autoimmune response. 3 In recent years, there has been increasing interest in the role of Tregs, which are important in the maintenance of peripheral immune tolerance. 4 Tregs can suppress immunemediated inflammation through a number of complementary mechanisms that may involve cell-cell contact and the release of regulatory cytokines that directly limit the responses of effector immune cells.
Several subtypes of Tregs exist, the most well studied being CD4 + cells that express high-level CD25 and the transcription factor forkhead box P3
(FOXP3), which is a critical determinant of Treg cell phenotype and function.
Treg deficiency or dysfunction is associated with autoimmune disease.
For example, in experimental animal studies, genetic or pharmacologic depletion of Tregs causes autoimmunity. 5, 6 Mutations of the FOXP3 gene in humans result in impaired Treg function and are associated with the 'immunodysregulation polyendocrinopathy enteropathy X-linked' (IPEX) syndrome, a rare disorder characterized by fulminant multi-organ autoimmunity. 7 In clinical studies, decreased levels of circulating CD25 + CD4 + T cells have been reported in patients with autoimmune disease, including vasculitis, rheumatic disease, juvenile idiopathic arthritis, and Kawasaki disease, [8] [9] [10] [11] [12] and are associated with high disease activity or poor prognosis. 8, 10, 12 Graft versus host disease (GvHD), which is a manifestation of allo-immunity following hematopoietic stem cell transplantation (HSCT), has also been associated with Treg cell deficiency.
These data have led to the hypothesis that augmentation of Tregs may be a useful therapeutic strategy in autoimmune disease. Treg augmentation has resulted in clinical improvements in numerous animal models of autoimmune diseases. 13 Furthermore, the administration of in vitro expanded CD4 + CD25 high CD127-Tregs has been found to be safe and may help to preserve β-cell function in children with T1D. 14, 15 Targeting Treg cell enhancement at the cellular and molecular levels may therefore be an attractive therapeutic strategy. Cytokines that can modulate and boost autoimmunity. In a study in which the genes for IL-2 were inactivated by gene targeting, the knockout mice died early due to lymphoproliferative syndrome accompanied by severe autoimmunity. 16 Neutralization of circulating IL-2 by anti-IL-2 monoclonal antibody has also been found to result in a number of autoimmune diseases, including gastritis, thyroiditis, sialadenitis, and severe neuropathy. 17 Autoimmunity associated with impaired IL-2 or IL-2R signaling is due to a failure in the development and homeostasis of Tregs. 18 Importantly, a low level of IL-2 receptor signaling is sufficient to provide these key functions to Tregs, while not supporting IL-2-dependent T effector activity. These latter observations provided some of the initial rationale for low-dose IL-2 therapy for autoimmunity. Figure   1 ). 33, 39 Recent studies have indicated that estrogen enhances the expression of CREMα, resulting in IL-2 suppression in human T lymphocytes. To summarize, at high doses, IL-2 activates immune Teffs; but at lower doses, IL-2 induces Tregs and also natural killer (NK) cell numbers and function to a lesser extent and in a dose-dependent manner. 18 However, it
is not known whether the therapeutic effects of low-dose IL-2 are solely attributable to the expansion of Tregs; in an animal model of experimental autoimmune encephalomyelitis (EAE), the IL-2 induced expansion of NK cells contributed to disease protection. 44 Overall, these data provide a strong rationale for the therapeutic use of low-dose IL-2 in the treatment of autoimmune inflammation.
Therapeutic Use of IL-2 in Autoimmune Disease
High However, administration of high-dose IL-2 was associated with significant toxicity including the development of the vascular or capillary leak syndrome (VLS/CLS). 45 At lower doses, IL-2 has been used to boost immune responses in patients with advanced HIV and induced a significant rise in the CD4 + T-cell count compared with patients treated with antiretroviral therapy alone. 46 Lowering the dose to reduce toxicity greatly reduces therapeutic efficacy as an immune stimulant. Further studies are required to confirm these findings.
In T1D, in a recent phase I/II study, 24 adult patients with T1D were randomized to three IL-2 dosing regimens. This was the first randomized placebo-controlled, double-blind clinical study of low-dose IL-2 in an autoimmune disease. IL-2 was well tolerated at all doses, with no serious AEs. Nonserious AEs, the most common of which were injection-site reaction and influenza-like syndrome, were slightly more frequent in the higher-dose group. Treatment with IL-2 increased in the proportion of
Tregs at all doses compared with placebo (see Figure 3) . 42 While the study was not powered to detect significant improvements of insulin secretion, is ongoing. 69 The ultra-low-dose IL-2 to fight T1D trial (DIABIL-2), a doubleblind, randomized, European phase IIb clinical trial, is also in progress. 70 In addition, ultra-low-dose IL-2 (0.1 or 0.2 × 10 6 IU/m 2 /day) was administered to 12 healthy volunteers with minimal AEs, mainly grade 1-2 injection site reactions. The levels of CD4 + Treg and CD56bright NK significantly increased at 7 days. 71 Low-dose IL-2 may affect the function of additional immune cells including innate lymphoid cells 2 (ILC2), which express CD25. 72 Finally, a recent case study has reported that low-dose IL-2-therapy induced a rapid, strong, and sustained reduction of disease activity as well a substantial and selective expansion of the Treg population in a SLE patient with increased disease activity. 73 Further cases of SLE improvements after low-dose IL-2 have also been recently reported.
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Practical Aspects of Administration of Low-dose IL-2
Patients with autoimmune diseases represent a heterogeneous group
and it may be difficult to predict an optimal IL-2 dosage a priori and this may also vary by underlying condition. Thus, caution must be exercised in -cells. 83 Moreover, combined therapy with IL-2 and rapamycin prevents T1D in animal models. 84 However, a phase I clinical trial involving combination therapy with IL-2 and rapamycin reported a temporary worsening of C-peptide production. In this study, nine adult patients were treated with rapamycin for 3 months. 85 During the first month, patients were also treated with 12 injections of IL-2, given at a dose of 4.5 × 10 6 IU, 3 times a week. Analysis of the 3-month data for seven patients revealed that they all had experienced a transitory but significant reduction in stimulated C-peptide responses. It is important to consider that IL-2 was given only during the first month, and yet the impaired secretory was observed at 3 months, while patients were still treated with rapamycin but were no longer treated with IL-2. Since patients were not evaluated earlier during the IL-2 course, the actual effects of this combination could not be directly evaluated.
Insulin secretion improved after rapamycin was discontinued. This should not be surprising, since rapamycin is known to have a negative impact on beta cell function, survival, and peripheral insulin resistance; rapamycin inhibits the mTOR pathways, causing beta cell toxicity, reduced beta cell size, mass, proliferation, impaired insulin secretion, increased apoptosis, autophagy, and peripheral insulin resistance. [85] [86] [87] Thus, at least in the T1D setting, the effects of rapamycin on pancreatic beta cell function may overcome any possible synergistic effect on Tregs when given with low-dose IL-2.
Adoptive cell therapy involving the combination of IL-2 and infusion of
Tregs is also the subject of clinical investigations, although research is at an early stage. This approach was shown to expand Tregs in vivo following allogeneic HSCT. 88 Translation of these promising data to clinical practice will require a robust method of generating large pure populations of Agspecific Tregs; an alternative is the use of ex vivo expanded Tregs 89 or freshly isolated donor Tregs. 90 Further clinical development of low-dose IL-2 in autoimmune diseases will likely require long-term administration of IL-2. A recent preclinical study showed that chronic low-dose IL-2 treatment does not suppress beneficial effector immune responses, for example against infectious agents or in response to vaccination, at doses that prevent autoimmune diabetes. 91 Another recent study found that low-dose IL-2 for GvHD prophylaxis after allogeneic HSCT reduced the frequency of infections and mediated the expansion of Tregs without diminishing its antiviral and anti-leukemic activity.
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Summary and Concluding Remarks
Autoimmune disease is chronic and debilitating, and there is an unmet need for safe and effective novel treatments. Autoimmunity is often characterized 
